title: [BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia].
abstract: Sixteen children with refractory hematological malignancies were treated with a combination of BH.AC, aclacinomycin-A, 6-MP and predonisolone (BH-AC.AMP protocol). They were ALL(6), ANLL(8), CML(1) and NHL(1). The CR ratio was 17% in ALL, 50% in ANLL, and blast crisis of CML was treated successfully but NHL failed in the induction remission. Major complications were vomiting, nausea, gastrointestinal bleeding, hematuria and hemorrhagic cystitis. More than 10 days or 120 mg/m2 administration of aclacinomycin-A was thought to induce more severe side effects.
authors.affiliation: Dept. of Pediatrics, Sapporo National Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Nakadate
authors.forename: Y
authors.initials: Y
authors.lastname: Hatayama
authors.forename: Y
authors.initials: Y
authors.lastname: Hatae
authors.forename: T
authors.initials: T
authors.lastname: Takeda
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007223:Infant; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D015250:Aclarubicin; D011239:Prednisolone; D015122:Mercaptopurine